114 related articles for article (PubMed ID: 11030493)
21. Excipients in valproic acid syrup may cause diarrhea: a case report.
Veerman MW
DICP; 1990 Sep; 24(9):832-3. PubMed ID: 2260339
[TBL] [Abstract][Full Text] [Related]
22. Effects of sodium valproate in 100 children with special reference to weight.
Egger J; Brett EM
Br Med J (Clin Res Ed); 1981 Aug; 283(6291):577-81. PubMed ID: 6790086
[TBL] [Abstract][Full Text] [Related]
23. Valproate-associated coagulopathies are frequent and variable in children.
Attilakos A; Katsarou E; Voudris K; Garoufi A
Epilepsia; 2007 Jan; 48(1):205-6. PubMed ID: 17241231
[No Abstract] [Full Text] [Related]
24. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
Dutta S; Reed RC; O'Dea RF
Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
[TBL] [Abstract][Full Text] [Related]
25. Occurrence of thrombocytopenia in psychiatric patients taking valproate.
Trannel TJ; Ahmed I; Goebert D
Am J Psychiatry; 2001 Jan; 158(1):128-30. PubMed ID: 11136646
[TBL] [Abstract][Full Text] [Related]
26. Gastrointestinal tolerance of divalproex sodium.
Wilder BJ; Karas BJ; Penry JK; Asconape J
Neurology; 1983 Jun; 33(6):808-11. PubMed ID: 6405304
[TBL] [Abstract][Full Text] [Related]
27. Comparative steady state serum levels of valproic acid administered as two different formulations--Deprakine and Orfiril.
Johannessen SI; Henriksen O
Acta Neurol Scand; 1979 Dec; 60(6):371-4. PubMed ID: 121513
[TBL] [Abstract][Full Text] [Related]
28. Chrono impact versus enteric coated valproate in Thai epileptic patients.
Towanabut S; Tiemkao S; Thammasupapong S; Kijjarak R; Arayawichanon A; Poungvarin N; Sirimaharaj S; Chaisewikul R; Asawavichenjinda T; Maneesuk S; Silpakit O
J Med Assoc Thai; 2005 Nov; 88(11):1651-9. PubMed ID: 16471115
[TBL] [Abstract][Full Text] [Related]
29. Thrombocytopenia and megakaryocyte dysplasia: an adverse effect of valproic acid treatment.
Gesundheit B; Kirby M; Lau W; Koren G; Abdelhaleem M
J Pediatr Hematol Oncol; 2002 Oct; 24(7):589-90. PubMed ID: 12368704
[No Abstract] [Full Text] [Related]
30. Lower effectiveness of divalproex versus valproic acid in a prospective, quasi-experimental clinical trial involving 9,260 psychiatric admissions.
Wassef AA; Winkler DE; Roache AL; Abobo VB; Lopez LM; Averill JP; Mian AI; Overall JE
Am J Psychiatry; 2005 Feb; 162(2):330-9. PubMed ID: 15677599
[TBL] [Abstract][Full Text] [Related]
31. EDTA-dependent pseudothrombocytopenia induced by valproic acid.
Yoshikawa H
Neurology; 2003 Aug; 61(4):579-80. PubMed ID: 12939450
[No Abstract] [Full Text] [Related]
32. [Studies of gastric tolerance of coated alka-butazolidin tablets].
Richter H; Atefie K; Gangl A; Thumb N
Wien Z Inn Med; 1970; 51(9):430-6. PubMed ID: 5316365
[No Abstract] [Full Text] [Related]
33. Prevalence and risk of thrombocytopenia with valproic acid: experience at a psychiatric teaching hospital.
Conley EL; Coley KC; Pollock BG; Dapos SV; Maxwell R; Branch RA
Pharmacotherapy; 2001 Nov; 21(11):1325-30. PubMed ID: 11714204
[TBL] [Abstract][Full Text] [Related]
34. Stuttering as a side-effect of divalproex sodium.
Aukst-Margetić B; Margetić B
Psychiatry Clin Neurosci; 2008 Dec; 62(6):748. PubMed ID: 19068016
[No Abstract] [Full Text] [Related]
35. Decreased platelet count in children with epilepsy treated with valproate and its relationship to the immature platelet fraction.
Kurahashi H; Takami A; Murotani K; Numoto S; Okumura A
Int J Hematol; 2018 Jan; 107(1):105-111. PubMed ID: 28879549
[TBL] [Abstract][Full Text] [Related]
36. [Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference].
Hoffmann F; Jancik BC; von Unruh GE
Arzneimittelforschung; 1986 Jul; 36(7):1118-22. PubMed ID: 3094548
[TBL] [Abstract][Full Text] [Related]
37. An alkaline phenylbutazone preparation.
Practitioner; 1969 Sep; 203(215):357-60. PubMed ID: 4308703
[No Abstract] [Full Text] [Related]
38. Sodium valproate and bone marrow suppression.
Smith FR; Boots M
Ann Neurol; 1980 Aug; 8(2):197-9. PubMed ID: 6775583
[TBL] [Abstract][Full Text] [Related]
39. The use of Monte Carlo simulations to study the effect of poor compliance on the steady state concentrations of valproic acid following administration of enteric-coated and extended release divalproex sodium formulations.
Ahmad AM; Douglas Boudinot F; Barr WH; Reed RC; Garnett WR
Biopharm Drug Dispos; 2005 Dec; 26(9):417-25. PubMed ID: 16216031
[TBL] [Abstract][Full Text] [Related]
40. IgM platelet autoantibody due to sodium valproate.
Sandler RM; Emberson C; Roberts GE; Voak D; Darnborough J; Heeley AF
Br Med J; 1978 Dec; 2(6153):1683-4. PubMed ID: 367512
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
